Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Revenue (2021 - 2024)

Historic Revenue for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q4 2024 value amounting to $26.2 million.

  • Amylyx Pharmaceuticals' Revenue fell 7928.38% to $26.2 million in Q4 2024 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year decrease of 8789.58%. This contributed to the annual value of $114.3 million for FY2024, which is 7351.5% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Revenue stood at $26.2 million for Q4 2024, which was down 7928.38% from $416000.0 recorded in Q3 2024.
  • Amylyx Pharmaceuticals' 5-year Revenue high stood at $126.6 million for Q4 2023, and its period low was $285000.0 during Q3 2021.
  • For the 4-year period, Amylyx Pharmaceuticals' Revenue averaged around $52.3 million, with its median value being $26.6 million (2022).
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Revenue surged by 2035045.7% in 2023, and later tumbled by 9962.81% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Revenue (Quarter) stood at $285000.0 in 2021, then skyrocketed by 9218.25% to $26.6 million in 2022, then soared by 376.75% to $126.6 million in 2023, then tumbled by 79.28% to $26.2 million in 2024.
  • Its last three reported values are $26.2 million in Q4 2024, $416000.0 for Q3 2024, and $1.0 million during Q2 2024.